Safety and Efficacy of Lutetium‐177 PSMA Radioligand Therapy in Metastatic Castration‐Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study)
[<sup>177</sup>Lu]Lu-PSMA-RLT demonstrates clinically meaningful benefits in survival and symptom management with an acceptable safety profile for mCRPC patients with extensive bone metastases. These findings support [<sup>177</sup>Lu]Lu-PSMA-RLT as a viable treatment option for this challenging population.
Authors
- Winnie Wing-Chuen Lam (ORCID: https://orcid.org/0000-0002-9813-9857)
- Kae Jack Tay (ORCID: https://orcid.org/0000-0003-0365-1899)
- Charlene Yu Lin Tang (ORCID: https://orcid.org/0000-0001-6051-7077)
- Ravindran Kanesvaran (ORCID: https://orcid.org/0000-0002-2351-881X)
- Sue Ping Thang (ORCID: https://orcid.org/0000-0002-7229-8737)
- Alvin Wong (ORCID: https://orcid.org/0000-0002-2020-9624)
- Kenneth Chen (ORCID: https://orcid.org/0000-0003-2304-4631)
- Wei Chua (ORCID: https://orcid.org/0000-0002-2021-3586)
- Cherie Wei Qi Ng
- Aaron Kian Ti Tong (ORCID: https://orcid.org/0000-0002-7703-8707)
- David Chee Eng Ng (ORCID: https://orcid.org/0000-0001-8554-3036)
- Wei Ying Tham
Institutions
- Singapore General Hospital (SG)
- National University Cancer Institute, Singapore (SG)
- Duke-NUS Medical School (SG)
- National Cancer Centre Singapore (SG)
- National University Health System (SG)
Publication Details
- Journal
- Asia-Pacific Journal of Clinical Oncology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1111/ajco.14195
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52